3D Printing Transforming Medical Implants: 4D Biomaterials Picks Up £1.6M Funding
A medtech company based in Nottingham, 4D Biomaterials, which has developed a new biomaterial used for 3D printing medical implants, has picked up £1.6 million in a recent funding round.
The investment round was led by DSW Ventures and backed by the MEIF Proof of Concept & Early Stage Fund, which is managed by Mercia and part of the Midlands Engine Investment Fund, Mercia’s own funds, and existing investor SFC Capital.
The investment will become the seventh in the portfolio for DSW Ventures, the UK-regional-focused venture capital business. 4D Biomaterials will use the funds to develop a range of products through partnerships with medical device companies and expand its team with the creation of five new jobs at its premises in MediCity.
Phil Smith, CEO of 4D Biomaterials said: “I am delighted to welcome DSW Ventures and Mercia on board at this exciting time for the company. The raise was oversubscribed by 60%, helped by the continuing support of SFC Capital and our angel investors. This puts us in a strong position as we move into the next phase of taking our products to market.”
Ellie Boardman, Investment Executive at DSW Ventures commented: “We have been extremely impressed by the team and product ever since our first meeting. The technology is constantly evolving, and we have been delighted to follow the company’s ongoing progress throughout the investment process. We believe 4D Biomaterials’ technology is truly innovative and have very high hopes for the company’s future.”
David Baker, Investment Manager at Mercia added: “4D Biotech is pioneering a new generation of biomaterials that offers benefits for patients and the health service alike. Not only could they speed up healing and remove the need for follow-on surgery, whether for tissue reconstruction or to remove the original implant. The funding will enable the company to find partners worldwide.”
Mark Wilcockson, Senior Investment Manager at the British Business Bank added: “We’re delighted to see this latest investment from the MEIF support new biotechnologies in the health sector. One of the key objectives of the MEIF is to see companies, like 4D Biomaterials, innovate, develop new products and expand. We encourage other businesses in the region to consider funding options available through the MEIF.”
Sajeeda Rose, Chief Executive of D2N2 LEP said: “Through the Midlands Engine Investment Fund, we want ambitious businesses to have the opportunity to grow and innovate, so I’m delighted to see this investment for 4D Bio. The region is known for its healthcare innovation and this investment will support 4D Bio in its growth and create highly skilled jobs for our communities.”
Only 3D printed biodegradable material
4D Biomaterials was founded by Andrew Dove and Andrew Weems. Its product 4Degra can be printed to the exact shape required in the form of an open-cell honeycomb structure and used to improve patient outcomes in a range of applications including tumour removal in breast cancer patients. 4Degra could also help patients recovering from other types of surgery and trauma, such as that caused by road traffic accidents.
As natural tissue grows back through the voids, the structure gradually erodes and is expelled harmlessly by the body. 4Degra is the only 3D printed material of its type that is also biodegradable. It was developed for over 15 years in Professor Andrew Dove’s research group at the University of Warwick and University of Birmingham.
People In This Post
Companies In This Post
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more